While this happened, Cantor Fitzgerald initiated its Astria Therapeutics Inc [ATXS] rating to an Overweight in a research note published on April 29, 2025; the price target was $47. A number of analysts have revised their coverage, including JMP Securities’s analysts, who began to cover the stock in late January with a ‘”a Mkt outperform”‘ rating. TD Cowen began covering ATXS with “Buy” recommendation on July 29, 2024. Evercore ISI started covering the stock on March 28, 2023. It rated ATXS as “an Outperform”.
Price Performance Review of ATXS
On Tuesday, Astria Therapeutics Inc [NASDAQ:ATXS] saw its stock fall -10.76% to $3.90. Over the last five days, the stock has lost -10.76%. Astria Therapeutics Inc shares have fallen nearly -56.38% since the year began. Nevertheless, the stocks have fallen -61.65% over the past one year. While a 52-week high of $12.92 was reached on 01/02/25, a 52-week low of $3.56 was recorded on 04/09/25. SMA at 50 days reached $5.28, while 200 days put it at $8.78.
Levels Of Support And Resistance For ATXS Stock
The 24-hour chart illustrates a support level at 3.55, which if violated will result in even more drops to 3.19. On the upside, there is a resistance level at 4.53. A further resistance level may holdings at 5.15. The Relative Strength Index (RSI) on the 14-day chart is 33.88, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.61, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 95.15%. Stochastics %K at 10.29% indicates the stock is a buying.
